cancer treatment drug arfolitixorin
Isofol Medical AB (publ) is a biotech company developing a new drug candidate, the cancer drug arfolitixorin, which is intended primarily for the treatment of colorectal cancer (CRC). It is the third most common form of cancer, and is in great need of more effective drugs. In the treatment of colorectal cancer, arfolitixorin is given in combination with the cytotoxin 5-FU (Fluorouracil) to increase tumour shrinkage and extend the life of the cancer patient. Arfolitixorin consists of the active substance MTHF ([6R]-5, 10-methylenetetrahydrofolate).
The folate-based prodrugs leucovorin and levoleucovorin are currently used in combination with 5-FU in the treatment of colorectal cancer. Isofol intends to replace these with arfolitixorin, with the primary goal of improving treatment outcomes for more than 370,000 colorectal cancer patients in the USA, Europe and Japan. Unlike leucovorin and levoleucovorin, which must be converted to MTHF in the body to be effective in cancer treatment, arfolitixorin consists of the active substance MTHF, meaning that no conversion is required. Therefore, arfolitixorin has the potential to provide a stronger antitumoral effect in all patients in combination with 5-FU therapy.
Through a global licensing agreement with Merck KGaA, Germany, Isofol has the exclusive right to develop and commercialise arfolitixorin in the oncology sector. The license agreement also affords Isofol access to the unique patent-protected manufacturing process for MTHF/arfolitixorin.
Isofol’s operations are based in Gothenburg and the company’s share is traded on the Nasdaq Stockholm.
Arfolitixorin animation- May 2019